CGRP Education & Research Forum
Already a member? Become a member Register
youtubeLinkedIn
News

Rimegepant

Rimegepant

In February 2020, Nurtec ODT (rimegepant) became the second oral CGRP receptor antagonist (gepant) to be approved for the acute treatment of migraine in adults. Rimegepant is formulated as a fast-acting orally disintegrating tablet (ODT), and its approval was supported by data including results of the Phase 3 Study 303 of rimegepant ODT, and additional clinical trials of rimegepant tablet including Study 301 and Study 302.


Download slideset »


« back to Slides